SEP 18, 2018 8:00 AM PDT

High-throughput CRISPR-Cas9 Genome Engineering in Primary T Cells

Sponsored by: Horizon Discovery
Speaker
  • Assistant Professor of Medicine, Northwestern University
    Biography
      Judd F. Hultquist, Ph.D., is an Assistant Professor of Medicine at Northwestern University in Chicago, Illinois. His lab specializes in the adaptation of proteomic and functional genomic technologies to primary models of disease to better understand the molecular dynamics of the host-pathogen relationship. His work on CRISPR technologies with Dr. Nevan Krogan at the University of California, San Francisco led to the development of the first gene editing platform for primary CD4+ T cells, the identification of several novel pathways that contribute to HIV replication, and the discovery of a new class of CRISPR inhibitors encoded by bacteriophages that maintain their function in mammalian cells. He is currently funded by the Third Coast Center for AIDS Research (CFAR) and the American Foundation for AIDS Research (amFAR) to apply CRISPR-Cas9 RNP technology to uncover the molecular mechanisms that underlie HIV latency and reactivation in patient reservoirs.

    Abstract
    DATE: September 18, 2018
    TIME: 08:00am PDT, 11:00am EDT
     
    CRISPR-Cas9 gene editing strategies have revolutionized our ability to engineer the genomes of diverse cell types and species for the robust functional interrogation of complex biological processes. Gene editing in primary T-cells represents an important research tool for the development of T-cell based immunotherapies, the study of the autoimmunity, the understanding of host-pathogen dynamics that drive HIV replication and latency, and creation of chimeric antigen receptor (CAR) T cells for the treatment of various cancers. While these cells have proven resistant to traditional transfection and transduction approaches for the CRISPR-Cas9 gene editing, recent advancements in ribonucleoprotein (RNP) delivery have allowed for efficient primary T-cell editing for the first time. In this webinar, we will present a workflow for the design and delivery of CRISPR-Cas9 RNPs to primary, human T-cells by electroporation. This platform supports the high-throughput, arrayed generation of hundreds of specific gene manipulations in only a few hours time without the use of recombinant DNA or lentiviruses and without the need for selection markers. This approach is widely adaptable to an array of downstream applications and protocols for the study of diverse T-cell processes.
     
    In this webinar, you will learn:
    • Optimal conditions for CRISPR-Cas9 gene editing in primary T cells using RNPs
    • Rules for designing, synthesizing, and validating efficient guide RNAs
    • Considerations for high-throughput functional screening
    • How this approach is being employed to better understand HIV replication and pathogenesis

     


    Show Resources
    You May Also Like
    DEC 02, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    OCT 08, 2020 7:00 AM PDT
    C.E. CREDITS
    OCT 08, 2020 7:00 AM PDT
    DATE: October 8, 2020 TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop thinking about ho...
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    OCT 29, 2020 6:00 AM PDT
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    APR 01, 2021 8:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    APR 01, 2021 8:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
    SEP 18, 2018 8:00 AM PDT

    High-throughput CRISPR-Cas9 Genome Engineering in Primary T Cells

    Sponsored by: Horizon Discovery

    Specialty

    Cancer Research

    Molecular Biology

    Biotechnology

    Cell Biology

    Immunology

    Crispr-Cas9

    Cell Culture

    Cancer Therapeutics

    Gene Expression

    Biochemistry

    Crispr

    Genomics

    Genetics

    Cancer Diagnostics

    Dna

    Geography

    North America49%

    Europe25%

    Asia19%

    South America4%

    Africa2%

    Oceania1%

    Registration Source

    Website Visitors50%

    WAVE Newsletter Promotion22%

    Email Promotions22%

    Social Media Promotions3%

    Trending Newsletter Promotion2%

    Other1%

    Job Title

    Research Scientist18%

    Student16%

    Scientist12%

    Executive10%

    Educator/Faculty8%

    Facility/Department Manager8%

    Medical Laboratory Technician7%

    Post Doc6%

    Medical Doctor/Specialist4%

    Clinical Laboratory Scientist3%

    Lab Management3%

    Biologist2%

    Marketing/Sales2%

    Consultant1%

    Organization

    Academic Institution19%

    Biotech Company16%

    Research Institute12%

    Hospital8%

    Clinical Laboratory5%

    Pharmaceutical Company5%

    Government5%

    Life Science Company4%

    Medical School4%

    Medical Center4%

    Industrial Company2%

    Non-Profit Organization2%

    Consultant2%

    Distribution/sales1%

    Other6%


    Show Resources
    Loading Comments...
    Show Resources
    Attendees
    • See more